Reimer A, Paul T, Kallfelz H C
Department of Pediatric Cardiology, Children's Hospital, Hannover Medical School, Federal Republic of Germany.
Am J Cardiol. 1991 Sep 15;68(8):741-4. doi: 10.1016/0002-9149(91)90646-3.
Propafenone was administered to 58 patients with a mean age of 3.2 years (range 0.1 to 16). Mean intravenous dose was 1.2 mg/kg body weight (range 0.3 to 1.5 mg). The final mean oral maintenance dose was 308 mg/m2 body surface area (range 200 to 600 mg/m2, 16.8 mg/kg body weight). After intravenous application, propafenone was effective in 21 of 36 patients; atrial flutter was converted in 1 of 5 patients, and reentry supraventricular tachycardia was controlled in 15 of 25 patients. Propafenone was partially or completely effective in 3 of 4 patients with chaotic atrial tachycardia. Junctional ectopic tachycardia was suppressed in 2 infants. Thirty-seven patients had oral treatment with a mean follow-up of 2.2 years. Propafenone was effective in 33 of 37 patients (89%); atrial flutter was controlled in 2 patients, ventricular ectopy was suppressed in 1 of 2 patients. In reentry supraventricular tachycardia, propafenone was effective in 25 of 28 patients. Chaotic atrial tachycardia (n = 3) and junctional ectopic tachycardia (n = 2) were controlled after successful intravenous therapy. Systemic side effects were rare. Two patients developed a proarrhythmic effect, and 1 patient with ventricular ectopy after repair of tetralogy of Fallot died suddenly during propafenone maintenance therapy.
58例患者接受了普罗帕酮治疗，平均年龄3.2岁（范围0.1至16岁）。静脉平均剂量为1.2mg/kg体重（范围0.3至1.5mg）。最终口服维持剂量为308mg/m²体表面积（范围200至600mg/m²，16.8mg/kg体重）。静脉应用后，36例患者中有21例有效；5例心房扑动患者中有1例转复，25例折返性室上性心动过速患者中有15例得到控制。4例紊乱性房性心动过速患者中有3例部分或完全有效。2例婴儿的交界性异位性心动过速得到抑制。37例患者接受口服治疗，平均随访2.2年。37例患者中有33例（89%）有效；2例心房扑动患者得到控制，2例室性早搏患者中有1例早搏受到抑制。在折返性室上性心动过速患者中，28例患者中有25例有效。3例紊乱性房性心动过速和2例交界性异位性心动过速在静脉治疗成功后得到控制。全身副作用罕见。2例患者出现促心律失常作用，1例法洛四联症修复术后有室性早搏的患者在普罗帕酮维持治疗期间突然死亡。
